College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
College of Pharmacy, Dankook University, Cheonan, Republic of Korea.
Pharm Dev Technol. 2022 Apr;27(4):414-424. doi: 10.1080/10837450.2022.2070644. Epub 2022 May 5.
A self-nanoemulsifying drug delivery system (SNEDDS) was developed to enhance the dissolution and oral bioavailability (BA) of revaprazan (RVP). Various SNEDDSs containing 200 mg of RVP were formulated using Capmul MCM, Tween 80, and Brij L4, and they were characterized according to their size, polydispersity index, and dissolution behavior. Dissolution rates of all SNEDDS formulations significantly ( < 0.05) improved with the formation of nanoemulsion with monodispersity. Formulation D resulted in RVP dissolution exceeding 70% at 2 h. Compared to raw RVP, SNEDDS exhibited a 4.8- to 7.4-fold improved effective permeability coefficient (P) throughout the intestine in the single pass intestinal permeability study and a 5.1-fold increased oral BA in the oral absorption assessment in rats. To evaluate the degree of lymphatic uptake, cycloheximide (CYC), a chylomicron flowing blocker, was pretreated prior to the experiment. This pretreatment barely affected the absorption of raw RVP; however, it greatly influenced the absorption of SNEDDS, resulting in an approximately 40% reduction in both the P value and oral BA representing lymphatic transport. Thus, we suggest that the SNEDDS formulation is a good candidate for improving oral absorption of RVP through enhanced lymphatic uptake.
自微乳药物传递系统(SNEDDS)被开发出来以提高雷贝拉唑(RVP)的溶解和口服生物利用度(BA)。使用 Capmul MCM、Tween 80 和 Brij L4 制备了含有 200mg RVP 的各种 SNEDDS,并根据其粒径、多分散指数和溶解行为进行了表征。所有 SNEDDS 制剂的溶解速率均显著提高( < 0.05),形成了单分散纳米乳。制剂 D 使 RVP 的溶解度在 2 小时内超过 70%。与原料药相比,SNEDDS 在单次肠通透性研究中表现出 4.8-7.4 倍的有效渗透系数(P)的改善,在大鼠口服吸收评估中表现出 5.1 倍的口服 BA 增加。为了评估淋巴摄取的程度,在实验前用环已酰亚胺(CYC)预处理,这是一种乳糜微粒流动阻断剂。这种预处理对原料药 RVP 的吸收几乎没有影响;然而,它极大地影响了 SNEDDS 的吸收,导致 P 值和口服 BA 分别降低约 40%,这代表了淋巴转运。因此,我们认为 SNEDDS 制剂是通过增强淋巴摄取来提高 RVP 口服吸收的良好候选物。